Tech Company Financing Transactions
Latigo Biotherapeutics Funding Round
Latigo Biotherapeutics closed a $150 million Series B funding round on 3/17/2025. Backers included Blue Owl Capital, 5AM Ventures and Access Biotechnology.
Transaction Overview
Company Name
Announced On
3/17/2025
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1300 Rancho Conejo Blvd. 305
Thousand Oaks, CA 91320
USA
Thousand Oaks, CA 91320
USA
Phone
Undisclosed
Website
Email Address
Overview
We are a clinical-stage company developing innovative non-opioid pain medicines with best-in-class profiles. Reducing pain lowers stress and facilitates healing. There is a large unmet need for a new class of medicines to treat pain, as the standard of care for pain has remained unchanged for decades.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Desmond Padhi
Vice President
Holly Carlisle
Vice President
Mike Kaufman
Vice President
Bryan Moyer
Browse more venture capital transactions:
Prev: 3/17/2025: Curevo Vaccine venture capital transaction
Next: 3/17/2025: Maxion Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs